Goldenwell Biotech, Inc. (GWLL) stock
Close on Oct 19, 2026Market cap $64.35MP/E –Yield –
Goldenwell Biotech, Inc. reported revenue of $55 for the twelve months to Jun 30, 2026. At the latest close the market valued the company at $64.35M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $64.35M
- P/E ratio
- –
- Price to sales
- 1170000.00
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $55
- Net income
- -$282.12K
- EPS, diluted
- $0.00
- Book value per share
- -$0.00
- Diluted shares
- 99M
Trading
- Previous close
- $0.60
- Open
- $0.65
- Day's range
- $0.65 – $0.65
- Volume
- 802
Market cap history
Month-end market cap since 2022, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | GWLL | S&P 500 | Difference | GWLL per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -5.8% | +0.6% | −6.4 pts | ||
| 3 months | -27.8% | +3.4% | −31.2 pts | ||
| Year to date | -77.6% | +13.3% | −90.9 pts | ||
| 1 year | +225.0% | +16.6% | +208.4 pts | ||
| 3 years | +160.0% | +86.4% | +73.6 pts | +37.5% | +23.1% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
About Goldenwell Biotech
Food and Kindred Products
Goldenwell Biotech, Inc. develops nutraceutical and dietary supplement products. Its offerings are organized into polypeptide freeze-dried powders and solid tablet formulations. The polypeptide products include bovine cardiac vascular active peptides, three-dimensional active collagen peptides designed for bodily absorption, and type II cartilage collagen supplements. The solid tablet line features Se Plus, an antioxidant and organoselenium compound, and Sugar Master, a cryogenic plant extract supplement. The company targets consumers seeking nutritional support, particularly middle-aged and elderly individuals, people exposed to environmental pollutants, and individuals experiencing selenium deficiencies.
Company profile, executives and historyGoldenwell Biotech stock: common questions
What is Goldenwell Biotech's stock price?
GWLL closed at $0.65 on Oct 19, 2026, up 8.33% on the day.
What is Goldenwell Biotech's market cap?
Goldenwell Biotech was worth $64.35M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is GWLL's P/E ratio?
Goldenwell Biotech lost money over the twelve months to Jun 30, 2026 (diluted EPS $0.00), so it has no meaningful P/E ratio.
How much revenue does Goldenwell Biotech make?
Goldenwell Biotech reported revenue of $55 for the twelve months to Jun 30, 2026.
Does Goldenwell Biotech pay a dividend?
No. Goldenwell Biotech has not paid a cash dividend over the last twelve months.
How has GWLL stock performed over the past year?
Including dividends, GWLL returned +225.0% over the past year, against +16.6% for the S&P 500.
Who are Goldenwell Biotech's competitors?
Companies most similar to Goldenwell Biotech by business, industry and size include LGSP, TCRG, STKH, BRQL, ODRS.
See a number that looks wrong?